• New immunotherapy regimens involving multiple agents represent a highly promising area of cancer research; a challenge is to identify optimal combinations.
• The current study was undertaken to evaluate the tumor microenvironment following intratumoral IMO-2125 therapy. This evaluation includes analysis of checkpoint expression in treated tumors as well as in distant tumors.
Intratumoral IMO-2125 induced potent antitumor activity and tumor checkpoint expression compared to subcutaneous administration in an A20 lymphoma model • Intratumoral IMO-2125 stimulated potent antitumor activity in preclinical models of lymphoma, colon carcinoma and melanoma.
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-Treatment led to increases in CD3+ TILs.
• Intratumoral IMO-2125 induced a systemic antitumor effect.
-Treatment led to decreases in tumor volume in treated and distant tumors.
• Intratumoral IMO-2125 modulated immune checkpoint gene expression, including IDO1, PDL1, TIM3, LAG3 and CTLA4, in both treated and distant tumor nodules.
• Together, these data showed that intratumoral IMO-2125 sensitized the tumor microenvironment for potential combinatorial effects with various checkpoint inhibitors.
• Planning for a clinical trial of intratumoral IMO-2125 in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients with metastatic melanoma is currently underway with study initiation expected in 4Q 2015.
Single and multiple intratumoral IMO-2125 doses induced potent antitumor activity and checkpoint gene expression
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